Photo: Josh Edelson/AFP via Getty Images

The Food and Drug Administration has approved an advanced treatment for mantle cell lymphoma, a rare type of cancer affecting white blood cells. The one-time therapy, made by Gilead Sciences, is branded as Tecartus.

Why it matters: This is the third federal approval of a CAR-T therapy, a new-age cancer treatment in which a person's own immune system cells are extracted, reengineered, and then infused back into the person's bloodstream.

The big picture: The other CAR-T therapies on the market are Kymriah (made by Novartis) and Yescarta (also made by Gilead).

By the numbers: Gilead set the list price of Tecartus at $373,000, the same as Yescarta.

  • However, that does not include other extraneous hospitalization costs.
  • Both of these drugs were part of Kite Pharma, which Gilead bought in 2017 for almost $12 billion.

Between the lines: Gilead said 87% of people who received Tecartus in a clinical trial responded to the infusion, but almost one out of five patients also experienced severe side effects associated with this kind of immunotherapy.

  • The trial was not randomized because the cancer is rare, and consequently, the FDA required a warning for side effects and will closely watch the therapy for safety issues while it's on the market.

Go deeper

Aug 4, 2020 - Health

Attorneys general ask feds to use march-in rights for remdesivir

Gilead helped develop remdesivir, an IV coronavirus treatment, with federal funding. Photo: Josh Edelson/AFP via Getty Images

Thirty-four state and territory attorneys general sent a letter today to federal health agencies asking the federal government to exercise march-in drug rights for remdesivir as a way "to help increase the supply of this drug and lower the price so it is accessible to our state residents."

The big picture: March-in rights — which would allow a patented drug developed with federal dollars to be licensed out to third parties — have never been exercised before. Gilead Sciences, the manufacturer and patent holder of remdesivir, did not immediately respond to requests for comment.

Updated 6 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 9 p.m. ET: 20,755,406 — Total deaths: 752,225— Total recoveries: 12,917,934Map.
  2. U.S.: Total confirmed cases as of 9 p.m. ET: 5,246,760 — Total deaths: 167,052 — Total recoveries: 1,774,648 — Total tests: 64,831,306Map.
  3. Politics: House Democrats to investigate scientist leading "Operation Warp Speed" vaccine projectMcConnell announces Senate will not hold votes until Sept. 8 unless stimulus deal is reached.
  4. 2020: Biden calls for 3-month national mask mandateBiden and Harris to receive coronavirus briefings 4 times a week.
  5. States: Georgia Gov. Brian Kemp to drop lawsuit over Atlanta's mask mandate.
  6. Business: Why the CARES Act makes 2020 the best year for companies to lose money.
  7. Public health: Fauci's guidance on pre-vaccine coronavirus treatments Cases are falling, but don't get too comfortable.

Trump says he intends to give RNC speech on White House lawn

President Trump speaking to reporters on South Lawn in July. Photo: Jabin Botsford/The Washington Post via Getty Images

President Trump told the New York Post on Thursday that he plans to deliver his Republican National Convention speech from the White House lawn, despite bipartisan criticism of the optics and legality of the location.

Why it matters: Previous presidents avoided blurring staged campaign-style events — like party conventions — with official business of governing on the White House premises, per Politico.